# EDGAR Filing Document

**Accession Number:** 0001109354
**File Stem:** 0001193125-25-312106
**Filing Date:** 2025-12
**Character Count:** 11388
**Document Hash:** d133822ffc3d8f8f9a4bec33baf07d11
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-312106.hdr.sgml**: 20251209

**ACCESSION NUMBER**: 0001193125-25-312106

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251209

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251209

**DATE AS OF CHANGE**: 20251209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRUKER CORP
- **CENTRAL INDEX KEY:** 0001109354
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043110160
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42828
- **FILM NUMBER:** 251557884

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MANNING RD
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 978663-3660

**MAIL ADDRESS:**
- **STREET 1:** 40 MANNING RD
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRUKER BIOSCIENCES CORP
- **DATE OF NAME CHANGE:** 20030721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRUKER DALTONICS INC
- **DATE OF NAME CHANGE:** 20000315

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 9, 2025

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Delaware | 000-30833 | 04-3110160 |
| (State or other jurisdiction of | (Commission | (I.R.S. Employer |
| incorporation) | File number) | Identification No.) |

---

40 Manning Road

Billerica**,** MA 01821

(Address of principal executive offices) (Zip Code)

**(**978**)** 663-3660

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on Which Registered** |
| Common Stock, $0.01 par value per share | BRKR | The Nasdaq Global Select Market |
| 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share | BRKRP<br>| The Nasdaq Global Select Market<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Section 5 - Corporate Governance and Management**

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) *Election of New Director* 

On December 8, 2025, the Board of Directors (the "Board") of Bruker Corporation (the "Company") approved an increase in the number of directors to expand the size of the Board by one director to a total of eleven directors, with such additional director assigned to Class III, and appointed Jack J. Phillips to fill the newly created vacancy on the Board, effective as of January 1, 2026. Mr. Phillips will initially serve as a director until the 2027 Annual Meeting of Stockholders.

Mr. Phillips' compensation for his services as a director will be consistent with that of the other non-employee directors of the Company, as described in the Company's definitive proxy statement with respect to the 2025 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 11, 2025. There are no other arrangements or understandings between Mr. Phillips and any other person pursuant to which he was elected as a director, and Mr. Phillips is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

The Company will file an amended Form 8-K to disclose Mr. Phillips' committee assignments once determined.

A copy of the press release announcing Mr. Phillips' appointment is attached to this report as Exhibit 99.1.

**Section 9 – Financial Statements and Exhibits**

**Item 9.01. Financial Statements and Exhibits.**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;(d) | &nbsp;&nbsp;Exhibits. | &nbsp;&nbsp;Exhibits. |
|  | Number | &nbsp;&nbsp;Description |
|  | &nbsp;&nbsp;99.1 | &nbsp;&nbsp;[<u>Press release dated December 8, 2025.</u>](brkr-ex99_1.htm) |
|  | &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | BRUKER CORPORATION<br>(Registrant) | BRUKER CORPORATION<br>(Registrant) |
| Date: December 9, 2025 | By: | /s/ GERALD N. HERMAN |
|  |  | Gerald N. Herman |
|  |  | *Executive Vice President and Chief Financial Officer* |

---

------

## Exhibit 99.1

Exhibit 99.1

![img53376846_0.jpg](img53376846_0.jpg)

**Bruker announces the addition of Diagnostics Industry leader<br>Jack Phillips to its Board of Directors as of January 2026**

**BILLERICA, Massachusetts - December 8, 2025** – Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry.

Frank H. Laukien, chairman, president and CEO of Bruker Corporation, stated: "Bruker is delighted to add Jack to our board of directors. His broad and deep diagnostics experience, strategic acumen and market development experience will be very valuable to Bruker and our board. I admire Jack's proven ability to translate scientific innovations into clinical impact for patient benefit and to accelerate profitable business growth in diagnostics. Jack's addition to our board is timely, as we broaden our infectious disease diagnostics portfolio, and increasingly leverage our unique disease biology research tools for opportunities in specialty diagnostics."

Jack Phillips served as President & CEO of Accelerate Diagnostics from 2020-2025, pioneering rapid antibiotic susceptibility testing (AST) technology for hospitals and infectious disease doctors combating serious bacterial infections, life-threatening sepsis and antibiotic resistance.

Previously, Jack was President & CEO of Roche Diagnostics North America from 2010-2020, where he led the portfolio across clinical chemistry, immunodiagnostics, as well as molecular, tissue and point-of-care diagnostics, and digital pathology, all further strengthening Roche's leadership position in the global in vitro diagnostics (IVD) industry.

From 1999-2010, Jack was Senior VP and General Manager, North America, for Ventana Medical Systems, helping establish tissue and companion diagnostics as standards of care. His career has centered on advancing innovation to clinical translation for patient benefit and business impact through strategy, market development and operational excellence. Jack serves on the Board of Trustees of Tucson Medical Center, and he previously was a board member of AdvaMedDx. He holds a B.S. in Marketing from Northern Kentucky University.

"It's a great honor to join the Board of Directors at Bruker Corporation, a company with an entrepreneurial culture and a unique dedication to innovation and translation that I really admire." said Mr. Phillips. "Throughout my career, I've seen diagnostics not as siloed technologies, but as a connected ecosystem that turns biological insight into clinical and economic impact, and I look forward to bringing that experience and vision to Bruker."

**About Bruker Corporation – Leader of the Post-Genomic Era** 

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics

------

systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.For more information, please visit www.bruker.com.

**Forward-Looking Statements**

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2024, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

**Investor Contact:**<br>Joe Kostka<br>Director, Investor Relations<br>Bruker Corporation<br>T: +1 (978) 313-5800<br>E: Investor.Relations@bruker.com<br>

------